3 Top Biotech Stocks to Buy in July
Over the past five years, biotech stocks have somewhat underperformed the S&P 500 benchmark. Controversies regarding drug pricing, the rising cost of innovation in medicine, and increased generic competition have all been chipping away at companies' bottom lines in the sector.
These risk factors have left the glass half full -- that is, they've created many bargain opportunities to buy biotech stocks at rock-bottom levels. Let's have a look at three such players -- Pfizer (NYSE: PFE), Regeneron Pharmaceuticals (NASDAQ: REGN), and Bayer (OTC: BAYR.Y) -- and why they are fantastic choices for investors on the hunt for value.
Image source: Getty Images.
Source Fool.com


